Introduction
Methods
Study Design
Study Population
Efficacy and Safety Assessments
Statistical Analysis
Results
Patient Demographics
Secukinumab 300 mg (n = 691) | Secukinumab 150 mg (n = 692) | Placebo (n = 692) | |
---|---|---|---|
Gender (male), n (%) | 477 (69.0) | 485 (70.1) | 484 (69.9) |
Age (years), mean (SD) | 44.9 (13.3) | 45.1 (13.4) | 44.7 (12.8) |
Range | 18–83 | 18–83 | 18–82 |
Race, n (%) | |||
White | 505 (73.1) | 499 (72.1) | 509 (73.6) |
Asian | 129 (18.7) | 129 (18.6) | 121 (17.5) |
Black | 9 (1.3) | 13 (1.9) | 13 (1.9) |
Other | 48 (6.9) | 51 (7.4) | 49 (7.1) |
Height (cm), mean (SD)a
| 171.2 (9.6) | 171.3 (10.2) | 171.6 (10.2) |
Range | 145.0–198.5 | 145.0–197.0 | 141.0–200.7 |
Weight (kg), mean (SD) | 86.6 (23.2) | 86.6 (23.2) | 86.0 (22.6) |
Range | 45.0–219.1 | 43.1–215.0 | 42.0–191.9 |
BMI (kg/m2), mean (SD)a
| 29.4 (6.9) | 29.4 (7.0) | 29.1 (6.9) |
Range | 17.4–67.4 | 16.5–79.7 | 16.2–71.2 |
PASI score, mean (SD) | 22.7 (9.4) | 22.8 (10.0) | 22.5 (9.7) |
Range | 11.2–72.0 | 12.0–69.6 | 10.6–72.0 |
IGA modified 2011 score, n (%) | |||
3 (Moderate disease) | 436 (63.1) | 439 (63.4) | 424 (61.3) |
4 (Severe disease) | 255 (36.9) | 253 (36.6) | 268 (38.7) |
Time since first psoriasis diagnosis (y), mean (SD) | 17.0 (12.0) | 17.9 (12.5) | 17.5 (12.2) |
Range | 0.5–61.5 | 0.5–69.0 | 0.5–68.1 |
Previous exposure to systemic psoriasis therapyb (yes), n (%) | 438 (63.4) | 447 (64.6) | 420 (60.7) |
Previous exposure to biologic systemic psoriasis therapyb (yes), n (%) | 146 (21.1) | 161 (23.3) | 147 (21.2) |
Previous exposure to non-biologic systemic psoriasis therapyb (yes), n (%) | 373 (54.0) | 393 (56.8) | 363 (52.5) |
Head and Neck Efficacy
Whole Body Efficacy
Safety
Preferred term, n (%) | 52 Weeks | 12 Weeks | |
---|---|---|---|
Secukinumab 300 mg (n = 690) | Secukinumab 150 mg (n = 692) | Placebo (n = 694) | |
Discontinuation due to adverse event | 21 (3.0) | 25 (3.6) | 9 (1.3) |
Any serious adverse event | 48 (7.0) | 48 (6.9) | 12 (1.7) |
Any adverse event | 575 (83.3) | 562 (81.2) | 340 (49.0) |
Most common adverse events (>5%) | |||
Nasopharyngitis | 172 (24.9) | 164 (23.7) | 60 (8.6) |
Headache | 79 (11.4) | 65 (9.4) | 36 (5.2) |
Diarrhea | 54 (7.8) | 45 (6.5) | 10 (1.4) |
Upper respiratory tract infection | 53 (7.7) | 64 (9.2) | 5 (0.7) |
Cough | 45 (6.5) | 21 (3.0) | 9 (1.3) |
Back pain | 37 (5.4) | 30 (4.3) | 10 (1.4) |
Hypertension | 35 (5.1) | 37 (5.3) | 12 (1.7) |
Arthralgia | 34 (4.9) | 38 (5.5) | 17 (2.4) |